8.Haematology

7/28/2019 8.Haematology

1/14

Annual Report 2009-2010Haematology

86

The Department o Haematology unctions both as a major clinical and laboratory medicine department. It plays a pivotal role

in the teaching o haematology to undergraduate medical students (MD), postgraduate students o medicine who have opted

to specialise in medicine, and Oman Medical Specialty Board (OMSB) residents in haematology, as well as medical laboratory

technicians in the B.Sc. Medical Laboratory Sciences course. Our laboratory provides state o the art haematology testing or the Uni-

versity Hospital (SQUH) and reerral services to other private hospitals, as well as highly specialised testing such as fowcytometric

and molecular haematological analysis or haematological condition diagnostics or the whole o Oman.

Haematology


2/14

87

academic

and

patientc

are

departments

H

aematology

Staff

FacultyChao Hung Ho, Proessor

Shahina Daar, Associate Proessor

David Dennison, Senior Consultant

Anil Pathare, Senior ConsultantNaglaa Fawaz, Senior Consultant

Mohammad Huneini, Consultant

Khalil Al-Farsi, Consultant

Murtadha Al-Kabori, Consultant

Nadeem Nusrut, Senior Registrar

Zeba Zabeen, Senior Registrar

Hammad Khan, Senior Registrar

Fehmida Zia, Registrar

Fauzia Wasim, Registrar

Abdulmanan Adulgaoor, Registrar

Mehwesh Taj, Registrar

Vinodh Panjwani, Senior House Ofcer

Najwa Abdulhameed, Senior House Ofcer

Ghasan Ageed, Senior House Ofcer

Mohamed Rehan, Senior House Ofcer

Moez HA Rhim, Senior House Ofcer

Support StaffStuart Donaldson, SuperintendentDavid Gravell, Chie Biomedical Scientist

Heidi M. Davis, Chie Biomedical Scientist

Shakila Ashra, Senior Biomedical Scientist

Ali Al-Marhoobi, Senior Biomedical Scientist

Hamood Al-Haddabi, Senior Biomedical Scientist

Rodrigo Villacrusis, Senior Biomedical Scientist

Maria Cicillia, Senior Biomedical Scientist

Abdulrehman N. Rashid, Senior Biomedical Scien-

tist

Qamariya Al-Abri, Biomedical Scientist

Mariyam Al-Brashdi, Biomedical Scientist

Sabah Al-Mahrooqi, Biomedical Scientist

Sahima Al-Mamari, Biomedical Scientist

Sai Al-Hosni, Biomedical Scientist

Hamed Al-Gheithi, Biomedical Scientist

Shoaib Al-Zadjali, Biomedical Scientist

Sumaya Al-Hinani, Biomedical Scientist

Asma A. Musleh, Biomedical ScientistKarima Al-Falahi, Biomedical Scientist

Badriya Al-Belushi, Biomedical Scientist

Bushra Al-Said, Biomedical Scientist

Mohammed Al-Rawahi, Biomedical Scientist

Muna Al-Maskari, Biomedical Scientist

Ishaq Al-Salmi, Biomedical Scientist

Deuel M. Labrador, Biomedical Scientist

Dr. SalamAl- K indiHead of Department


3/14


88

Enrique O. Pedojan, Biomedical Scientist

Eurosina Alverez, Biomedical ScientistJulian Neson, Biomedical Scientist

Mohan Doraiswamy, Biomedical Scientist

Nestor Naniong, Biomedical Scientist

Rene Gabucay, Biomedical Scientist

Allan S. Aurelio, Biomedical Scientist

Adela Angeles, Biomedical Scientist

Melani Tauro, Biomedical Scientist

Malvin J. Wee Li, Biomedical Scientist

Vardarajan Nelvoy, Biomedical ScientistLancy Henry, Biomedical Scientist

Rhea Misquith, Biomedical Scientist

Rosamma Soney, Head Sta Nurse

Binny Sam, Senior Sta Nurse

Rose Saly, Sta Nurse 2

Mary Kurian, Sta Nurse - ICH3

Victoria G Menezes, Sta Nurse 2

Shiney Thomas, Sta Nurse 2

Salva Kumari, Sta Nurse 2

Bindu Shiby, Sta Nurse 2

Eman Al-Homaidi, Coordinator

Tomichan Varghese, Coordinator

Ibrahim Al-Amri, Coordinator

Highlights of the Year 2009-2010In 20092010, the clinical unit treated patients with a vast range o haematological disorders, both as in-

patients and outpatients. In addition, the Department runs a thalassaemia day care unit. In 2010, it oered

comprehensive care or about 142 patients with transusion dependent thalassaemia. O national interest is

the successul bone marrow transplant programme, run by this department. By the end o Dec. 2010, a total

o 175 allogeneic bone marrow transplants had been perormed in this centre, with results as good as those

rom the best centres around the world.


4/14

89

academic

and

patientc

are

departments

H

aematology

Teaching ProgrammesUNDERGRADUATE PROGRAMME

In this period the Department has: 1) participated in teaching the Haemato-Lymph-Vascular course to the

third year students; 2) developed and taught a new module in phase 2 o the undergraduate curriculum on

hemato-lymphatic-immunology; 3) participated and coordinated the various courses in phase 2 o the new

curriculum, in particular Integrated modules I, II, III; 4) run a 5 week course on case-based learning, in Haema-

tology or the 5th year students in the Integrated Lecture Series (ILS); 5) participated in bedside clinical teach-

ing in Medicine; 6) run Laboratory rotations or 6 groups o 7th year students, each rotation o 5 days duration;

7) run a B.Sc MLS degree course or training undergraduate biomedical scientists.

POSTGRADUATE PROGRAMME

The Department has developed and taught the Haematopathology course along with the Ministry o Health

Royal Hospital, which is aliated with the Oman Medical Specialty Board. There are 6 residents at various

stages o training in the programme.

Clinical & Diagnostic ServicesThe clinical services centre on the ollowing major areas; adult outpatients, adult inpatients; bone marrow

transplantation, sickle cell anaemia programe; the leukaemia, lymphoma and myeloma programme, and thethalassaemia day care unit. The laboratory services likewise cover specialised areas: haemostasis, fowcy-

tometry, haemoglobinopathy, molecular diagnostics, general laboratory haematology and the blood transu-

sion service which includes blood donation, storage, irradiation, plasmapheresis and exchange and apheresis

acilities as well as the blood grouping and cross matching laboratory.

BONE MARROW TRANSPLANTATION PROGRAMME

The bone marrow transplant programme, established in 1995 in the Department, serves the entire coun-

try and continues to provide curative treatment or patients with haematologic malignancy, bone marrow

ailure and potentially atal genetic diseases. In 2010, 22 transplants were perormed, making a total o 175transplants since 1995. The results o this transplant centre are comparable with those o the best centres

worldwide. Importantly, the cost per transplant is a raction o what is charged in other countries.

SICKLE CELL PROGRAMME

The Department looks ater a large number o patients with sickle cell disease (SCD) providing acute medical

care, as well as genetic counselling and preventive programmes (vis--vis cord blood testing), and organising

and guiding the patients and the medical community in the care o SCD. Recently the role o the Department


5/14


90

has been highlighted through our community outreach programmes via the Hereditary Blood Disorders

Society.

LEUKAEMIA LYMPHOMA AND MYELOMA PROGRAMME

The Department is now an important tertiary care centre or most reerrals or adult haematological malig-

nancies particularly leukaemias, and myeloma. Our patients are able to receive state-o-the-art care both in

terms o diagnostic and therapeutic modalities, including bone marrow transplant (BMT) and the advanced

molecular diagnostics needed or proper ollow-up.

THALASSAEMIA UNIT

The Department has been looking ater about 150 patients with thalassaemia, delivering comprehensivecare including blood transusions, chelation therapy, and regular meticulous monitoring or the side eects

and complications o the disease and its treatment. The unit is a centre o excellence in the region with heavy

involvement in care and research including participation in an international drug trial (Exjade). The unit has

recently acquired the latest state o art MRI T2* equipment or monitoring the cardiac and liver iron overload

status which has improved the monitoring o iron overload in these patients.

HAEMATOLOGY CLINICS AT THE NEW SOHAR HOSPITAL

The Department conducts a monthly haematology clinic at the new Sohar Hospital. The clinic is run on

rotation basis by one o the Departments haematology consultants. They are assisted locally by Dr Ali Al-Madhani, rom the Department o Medicine, Sohar Hospital.

GENERAL LABORATORY SERVICES

The Haematology Laboratory caters to the entire hospital and additionally receives reerral samples rom

all over Oman or routine and advanced haematology laboratory testing. The laboratory is subdivided into

various sections including general haematology, haemoglobinopathy, haemostasis and special haematol-

ogy, blood banking and donor room services, and the molecular division.

MOLECULAR RESEARCH AND DIAGNOSTIC LABORATORY

The Department now oers DNA diagnostic acilities or several thrombophilic disorders, haemoglobin dis-

orders, immune deciency syndromes and malignant haematology, especially or acute and chronic leu-

kaemia. The section is also involved in the monitoring o the transplant progress by chimerism studies in

post-transplant patients.


6/14

91

academic

and

patientc

are

departments

H

aematology

CORD BLOOD BANK

The Department, in collaboration with the Department o Obstetrics & Gynaecology, has now set up a CordBlood Bank. We have standardised the collection and storage o cord blood samples. Collection o cord blood

is currently done under two programs: a) sibling cord blood (SCB) and, b) unrelated cord blood (UCB). Up to

August 2010, we had collected a total o 73 SCB units and 41 UCB units. We have so ar used 3 SCB units or

sibling cord blood transplantation.

APHERESIS UNIT OF THE BLOOD BANK

The Department has now installed the Baxter Amicus and Cobe Spectra apheresis systems and our apheresis

nurses and technicians are trained in their use. Both o these systems are now in routine use or harvesting

stem cells rom donors in the Departments Bone Marrow Transplantation program and platelet apheresis.Moreover, apheresis services are now made available, in consultation with the attending haematologist on

duty, to the SQUH wards and ICU units whenever the need or plasmapheresis or plasma exchange arises.

BUSULPHAN PHARMAKOKINETICS

Optimisation o busulphan dosage in patients undergoing bone marrow transplantation is recommended

in order to reduce the toxic eects associated with high drug levels. The API 150 EX LCMS system which has

been installed or the research project on intravenous versus oral busulphan in BMT or thalassaemia is now

ully operational. The section looks ater the busulphan pharmakokinetics in patients undergoing BMT to as-

sess the blood levels o the drug in order to optimise the treatment protocols.

Table 1: Haematology Laboratory Activities

Year

Jan-Dec

Number o Patients % increase over last

year

Tests & Procedures % Change on

previous year

2007 11,7631 -12.1% 48,5060 -2.5%

2008 14,7799 +25.6% 59,8309 +23.3%

2009 17,7568 +20.1% 71,2520 +19.1%

2010 19,8109 +11.6% 77,8662 +9.3%


7/14


92

Table 2: Clinical Workload

Year

Jan-Dec

Haematology

Inpatients

% Change

on Previ-

ous Year

Haematology

Day Care

% Change

on Previ-

ous Year

Haematology

Outpatients

% Change on

Previous Year

2007 1416 +5.3% 3078 -10.5% 2826 +6.2%

2008 1409 -0.5% 3035 -1.4% 3428 +21.3%

2009 1887 +33.9% 3127 +3.0% 4181 +22.0%

2010 1869 -1.0% 3271 +4.6% 4407 +5.4%

Research

RESEARCH PROJECTS

Establishment o a national acility in stem cell translation research or novel cellular-based therapiesand tissue repair

Project Code: SR/MED/ HAEM/09 /01; Dates: 20092011

Value: OR 165,000; Project Funder: His Majestys Strategic Fund, Oman

Investigators: Dr. David Dennison, Dept. Haematology, SQU; Dr. Sultan Al-Maskari Dept.Surgery, SQU; Dr. Anil Pathare, Dept. Haematology, SQU; Dr. Salam Al-Kindi,Dept. Haematology, SQU; Dr. Khalil Al-Farsi, Dept. Haematology, SQU; Dr.Mohammed Al-Hunieni, Dept. Haematology, SQU; Dr. Nagla Fawaz, Dept.Haematology, SQU; Ms. Qamariya Al-Abri, Dept. Haematology, SQU; Ms.Sahima Al-Maamaari, Dept. Haematology, SQU; Ms. Sabah Al-Mahrooqi,Dept. Haematology, SQU; Ali Al-Mahroobi, Dept. Haematology, SQU; HamedAl-Gheiti, Dept. Haematology, SQU; Shoaib Al-Zadjali, Dept. Haematology,SQU; Melanie Tauro, Dept. Haematology, SQU; Dr. Yasser Wali, Dept. Child

Health, SQU; Dr. Abdulhakeem Rawas, Dept. Child Health, SQU; Dr. Mu-hanna Al-Muslahi, Dept. Haematology, Royal Hospital, Oman ; Dr. HamoudAl-Dhuli, Dept. Radiology, SQU; Dr. Rashid Al- Sukaiti, Dept. Radiology & Mo-lecular Imaging, SQU; Dr. Shyam Ganguly, Dept. Family Medicine & PublicHealth, SQU; Dr. Helmut Schuster, Dept. Microbiology & Immunology, SQU;Dr. Adeeb Al-Zoubi, Jordan University, Jordan.


8/14

93

a

cademic

and

patientc

are

departments

H

aematology

Molecular Genetics o alpha globin gene expression in native Omani Population: Towards understanding

the molecular basis o alpha thalassaemia and impact on clinical expression o beta thalassaemia andsickle cell disease

Project Code: RC/MED/HAEM/10/01; Dates: 2010-2012

Value: OR 68,300; Project Funder: The Research Council, Oman

Investigator: Dr. Salam Al-Kindi, Dept. Haematology, SQU; Dr. Muhammed Al-Hunaini,Dept. Haematology, SQU; Dr. Khalil Al-Farsi, Dept. Haematology, SQU; Dr.Anil Pathare, Dept. Haematology, SQU; Dr. Nagla Fawaaz, Dept. Haematol-ogy, SQU; Shoaib Al-Zadjali, Dept. Haematology, SQU; Hamood Al-Haddabi,Dept. Haematology, SQU; Dr. R. Krishnamoorthy, INSERM U 763, Paris, France.

Pharmacogenomic actors aecting wararin dosing: Rationale or prospective genetic screening beoreanticoagulation therapy

Project Code: IG/MED/HAEM/09/01; Dates: 20092010

Value: OR 5,400; Project Funder: Sultan Qaboos University

Investigator: Dr. Anil Pathare, Dept. Haematology, SQU; Dr. Salam Al-Kindi, Dept. Hae-matology, SQU; David Gravell, Dept. Haematology, SQU; Shoaib Al-Zadjali,Dept. Haematology, SQU; Hamood Al-Haddabi, Dept. Haematology, SQU; Dr.R. Krishnamoorthy, INSERM U 763, Paris , France.

Genetic basis o variable expression o etal hemoglobin in sickle cell disease and beta thalassaemiapatients rom Oman



Investigator: Dr. Anil Pathare, Dept. Haematology, SQU; Dr. Salam Al-Kindi, Dept. Hae-matology, SQU; Mohammed Al-Hunieni, Dept. Haematology, SQU; Dr.Khalil Al-Farsi, Dept. Haematology, SQU; Dr. Shahina Daar, Dept. Haematol-

ogy, SQU; Shoaib Al-Zadjali, Dept. Haematology, SQU; Sahima Al-Maamari,Dept. Haematology, SQU; Dr. R. Krishnamoorthy, INSERM U 763, Paris, France.

Saety profle and therapeutic use o back ink rom Omani fshes in two experimental models o osteopo-rosis in rats



Investigators: Dr. Haddia Berehi, Dept. Medical Physics, SQU; Pro. Badreldin Ali, Dept.


9/14


94

Pharmacology & Clinical Pharmacy, SQU; Dr. Kamran Malik, Dept. Surgery,

SQU; Dr. Khaled Malgat, Dept. Chemistry, SQU; Dr Aisha Al-Hamadani, Dept.Pathology, SQU.

Role o von Willebrand actor on the occurrence o vaso-occlusive crisis in patients with sickle celldisease.

Project Code: IG/MED/ HAEM/10/02; Dates: 20102012


Investigator: Mohammed Al-Hunieni, Dept. Haematology, SQU; Dr. Anil Pathare, Dept.Haematology, SQU; Dr. Pro. Ho Chao-Hung, Dept. Haematology, SQU; Da-

vid Gravell, Dept. Haematology, SQU; Shoaib Al-Zadjali, Dept. Haematology,SQU; Qamariya Al-Abri, Dept. Haematology, SQU; Vinod Panjwani, Dept.Haematology, SQU; Hamed Khan, Dept. Haematology, SQU.

Prevalence o abnormal bone densitometry fndings in individuals with homozygous beta thalassaemia

Project Code: MREC #325; Dates: 201011

Value: Ununded; Project Approval: Sultan Qaboos University

Investigators: Dr. Shahina Daar, Dept. Haematology, SQU, Dr. Samir Hussein, Dept. Radiol-ogy & Molecular Imaging, SQU, Mohammed Al-Hunieni, Dept. Haematol-

ogy, SQU.

Prevalence o optimal monitoring o kidney unction in relation to patients with thalassaemia.

Project Code: MREC #351 Dates: 20102011


Investigators: Dr. Shahina Daar, Dept. Haematology, SQU; Dr. Sunil Bhandari, Hull YorkMedical School, UK; Dr. Khalid Al-Rasadi, Dept. Biochemistry, SQU; HumoudAl-Dhuhli, Dept. Radiology & Molecular Imaging, SQU; Surekha Mevada,Dept. Child Health, SQU; Dr Hammad Khan, Dept. Haematology, SQU.

Evaluation o cardiac and liver iron load by MRI T2*

Project Code: MREC #361; Dates: 20102011


Investigators: Dr. Shahina Daar, Dept. Haematology, SQU; Humoud Al-Dhuhli, Dept. Radi-ology & Molecular Imaging, SQU.


10/14

95

a

cademic

and

patient

care

departments

H

aematology

Prevalence o endocrinopathies in thalassaemia major patients, correlation with total body iron load and

cardiac iron loadProject Code: MREC #344; Dates: 20102011


Investigators: Dr. Shahina Daar, Dept. Haematology, SQU; Dr Khalil Al Farsi, Dept. Haema-tology, SQU; Dr. David Dennison, Dept. Haematology, SQU; Dr Fehmida Zia,Dept. Haematology, SQU; Dr Moez HA Rhim Dept. Haematology, SQU.

Clinical eects o Nicosan TM to reduce the occurrence vasoocclusive crisis patients with sickle cell dis-ease

Project Code: MREC# 352; Dates: 2010


Investigators: Dr. Salam Al Kindi, Dept. Haematology, SQU

Retrospective analysis o Sickle cell patient with PORT-A-CATH insertion to analyze complications oPORT-A-CATH in patients with Sickle cell Disease



Investigators: Dr. Salam Al Kindi, Dept. Haematology, SQU

Evaluation o Cardiac and Liver Iron Load by Cardiac MRI (T2*)

Project Code: MREC# 361; Dates: 2010Value: Ununded; Project Approval: Sultan Qaboos University

Investigators: Dr. Shahina Daar, Dept. Haematology, SQU

Causes and Outcome o Fever in patients with Sickle cell Disease

Project Code: MREC# 362; Dates: 2010Value: Ununded; Project Approval: Sultan Qaboos University

Investigators: Dr. Khalil Al Farsi, Dept. Haematology, SQU

Acute Chest Syndrome in Sickle Cell Patients during Pregnancy: Risk Factors and Outcome




11/14


96

Investigators: Dr. Khalil Al Farsi, Dept. Haematology, SQU.

Causes o Prolonged Prothrombin Time and Activated Partial Thromboplastin Time



Investigators: Dr. Khalil Al Farsi, Dept. Haematology, SQU.

RESEARCH PUBLICATIONS & BOOKS

Journal Publications

1. Pathare AV, Taher A, Daar S. Deerasirox (Exjade(R)) signicantly improves cardiac T2* in heavily iron-over-loaded patients with beta-thalassemia major. Ann Hematol 2010; 89:4059.

2. Alkindi S, Al Zadjali S, Al Madhani A, Daar S, Al Haddabi H, Al Abri Q, Gravell D, Berbar T, Pravin S, Pathare A, Krish-

namoorthy R. Forecasting hemoglobinopathy burden through neonatal screening in Omani neonates.

Hemoglobin 2010; 34:13544.

3. Alkaabi JK, Pathare A. Pattern and outcome o vascular involvement o Omani patients with Behcets dis-

ease. Rheumatol Int 2010; Feb 4, [Epub ahead o print].

4. Battersby AJ, Knox-Macaulay HH, Carrol ED. Susceptibility to invasive bacterial inections in children with

sickle cell disease. Pediatr Blood Cancer 2010; 55:401

6.

5. Alkindi S, Khan S, Riyami D, Farooqi M, Pathare A. Coexistence o immune thrombocytopenic purpura and

idiopathic membranous glomerulonephritis successully treated with rituximab. Platelets 2010; 12 July.

[Epub ahead o print].

7. Taher AT, Musallam KM, Karimi M, El-Beshlawy A,Belhoul K, Daar S, Saned M, Cassaretti C, Cappellini M. Splenec-

tomy and thrombosis: the case o thalassaemia intermedia. J Thromb Haemost 2010; June [Epub ahead

o print].

8. Taher A, Musallam K, El-Beshlawy A, Karimi M, Daar S, Belhoul K, et al. Age-related complications in treatment-

nave patients with thalassemia intermedia. Br J Haem 2010; April [Epub ahead o print].

9. Taher A, Al Jeri A, Elaly MS, Al Zir K, Daar S, Roail D, et al. Improved treatment satisaction and convenience

with deerasirox in iron-overloaded patients with thalassaemia: Results rom the Escalator Trial. Acta

Hematologica 2010; 123:2205.

10. Taher A, Musallam K, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Overview o practices in thalassemia

intermedia management aiming or lowering complication-rates across a region o endemicity: the OP-

TIMAL CARE study. Blood 2010; 115:188692.


12/14

97

a

cademic

and

patient

care

departments

H

aematology

11. Al-Khabori M, Minden MD, Yee KWL, et al. Improved survival using an intensive, pediatric-based chemother-

apy regimen in adults with T-cell acute lymphoblastic leukemia. Leukemia & Lymphoma 2010; 51:61

5.12. Khabori MA, El-Emary M, W Xu, Guyatt G, et al. Impact o intensity o the conditioning therapy in patients

aged 40 to 60 years with acute myeloid leukemia/ myelodysplastic syndrome undergoing allogeneic

transplantation. Bone Marrow Transplantation 2010; July [Epub ahead o print].

13. de Almeida JR, Al Khabori M, Guyatt GH, et al. Combined corticosteroid and antiviral treatment or Bells

palsy: Asystematic review and meta-analysis. JAMA 2009; 302:98593.

14. El-Emary M, Khabori MA, Buitron N, et al. Long term outcomes o allogeneic stem cell transplantation or

chronic lymphocytic leukemia. Biol Blood Marrow Transpl 2010; 16:S2756.

CONFERENCE & SEMINAR PRESENTATIONS

Conference Presentations

International

1. Pathare AV, Al Zadjali S, Misquith R, Alkindi S, Dennison D , Pravin S, Berbar T, Krishnamoorthy R. Pharmacoge-

nomic variants o CYP2C9, CYP4F2 and VKORC1 and its relation to wararin response in native Omani

patients. 15th Congress o the European Hematology Association. Barcelona, Spain, 1013 June 2010.

2. Daar S, Al Salmi F, Ableen V, Jacob W, Jabeen Z, PathareA. T2* MRI- an eective tool to increase chelation com-

pliance in thalassaemia major. 15th

Congress o the European Hematology Association. Barcelona, Spain,1013 June 2010.

Conference Posters

International

1. Al-Khabori MK, El-Emary M, Guyatt G, Galal A, Kuruvilla J, Lipton JH, et al. Impact o the intensity o condition-

ing therapy on the outcomes o patients aged 40 to 60 years with acute myeloidleukemia/myelodys-

plastic syndrome undergoing allogeneic hematopoietic cell transplantation. American Society o Hae-

matology, Annual Meeting. New Orleans, USA, 58 December 2009. Pub. in: Blood (ASH Annual Meeting

Abstracts) 2009; 114:1202.2. Al-Khabori MK, Almeida J, Guyatt G, Kuruvilla J, Crump M. High dose chemotherapy and autologous stem cell

transplantation in the primary therapy o advanced ollicular lymphoma in adults: A systematic review

and meta-analysis o randomized clinical trials. American Society o Haematology, Annual Meeting.

New Orleans, USA, 58 December 2009. Pub. in: Blood (ASH Annual Meeting Abstracts), 2009; 114:2314.

3. Khabori MA, El-Emary M, Messner H, et al. Two-digit resolution typing o class-I human leukocyte antigen

(HLA) does not compromise outcomes in adults undergoing matched unrelated allogeneic bone marrow


13/14


98

transplantation. Symposium o the American Society or Blood and Marrow Transplantation. Milano

Italy, 27

29 March 2009. Pub. in: Blood Marrow Transpl 2010; 16:S219.4. AlMadhani A, Alkindi S, AlZadjali S, Misquith R, Pathare A, Krishnamoorthy R. Neonatal screening o new-

borns: Targeted versus universal approach as a cost eective strategy. 15th Congress European Hematol-

ogy Association. Barcelona, Spain, 1013 June 2010.

5. Ho CH, Gravell D. Can very high value o D-dimer predict the presence o thromboembolic disorders? 15 th

Congress o the European Hematology Association. Barcelona, Spain, 10-13 June 2010. Pub. in: Haemato-

logica 2010; 95:292 (Abstract 699).

6. Taher A, Musallam K, El-Beshlawy A, Karimi M, Daar S, Belhoul K, et al. Age-related complications in treatment-

nave patients with thalassemia intermedia. 15th

Congress o the European Hematology Association.Barcelona, Spain, 1013 June 2010.

7. Musallam K, Cappellini M, El-Beshlawy A, Karimi M, Daar S, Belhoul K, et al. Splenectomy and thrombosis: the

case o thalassaemia intermedia. 15th Congress o the European Hematology Association. Barcelona,

Spain, 10-13 June 2010.

National

1. Pathare AV, Al Zadjali S, Misquith R, Alkindi S, Krishnamoorthy R. Pharmacogenomic variants o CYP2C9, CY-

P4F2 and VKORC1 and its relation to wararin response in native Omani patients. University Day. Sultan

Qaboos University, Muscat, Oman, 2 May 2009.

Seminar Presentations

International

1. Alkindi S. Sickle cell disease program at the Sultan Qaboos University Hospital, 1 st Haematology Update Conerence.

Manama, Bahrain, May 2010.

2. Daar S. Iron chelation in Beta thalasaemia, 1st Haematology Update Conerence. Manama, Bahrain, May 2010.

3. Daar S. Myocardial T2* MRI or Diagnosis & Follow-up o cardiac Siderosis in Thalassaemia; 1st Haematology UpdateConerence. Manama, Bahrain, May 2010.

4. Daar S. Exjade The Oman Experience. Gul Thalassaemia Workshop. Dubai, UAE, Feb 2010,

National

1. Alkindi S. Update on CML, Crown Plaza, Muscat, Oman, November 2009.

2. Alkindi S. Update on Current status o SCD in Oman. Advanced General Medical Conerence, Sultan Qaboos Unvier-sity, Muscat, Oman, February 2010.

3. Alkindi S. Comprehensive care o patients with Sickle cell disease, Sohar Hospital, Oman, March 2010.


14/14

99

a

cademic

and

patient

care

departments

H

aematology

4. Alkindi S. General overview o hereditary blood disorders, Hereditary Blood Disorder Society, Muscat, Oman, April

2010.5. Alkindi S. Update on Bortezomib. Grand Hyatt, Muscat, Oman, May 2010.

6. Alkindi S. Laboratory Investigations & Management o thrombophilia. Ibra Hospital, Oman, May 2010.

7. AlFarsi K. Clinical cases with thrombophilia. Oman Hematology Forum, Blood Club. Al Sawadi Hotel, Oman, Jan-

uary 2010.

Documents

8.Haematology